A wireless implantable device that remotely monitors pulmonary artery pressure offers reliable safety and is linked to a significant reduction in the risk for heart failure-related hospitalisation.
Vutrisiran numerically reduced the risk of the primary composite end point of all-cause mortality and recurrent ...
The NYHA classification was originally designed as a clinical and not a research tool. [7] It was never meant to serve the purpose of establishing the diagnosis of HF. It was designed purely as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results